Sign In
Buy AZN
$183.02
+2.00 (+1.10%)
At Close: Jun 24, 2026
AstraZeneca (AZN) Drugs Get CHMP Recommendation for Breast Cancer
12:21pm, Tuesday, 28'th Jun 2022
The EMA's Committee for Medicinal Products for Human Use recommends granting marketing approval to AstraZeneca's (AZN) cancer drugs, Enhertu and Lynparza, for treating certain patients with breast can
These 3 Nasdaq-100 Leaders Have More Upside
02:00am, Tuesday, 28'th Jun 2022
Through June 24th, all but 16 of the popular benchmark's names were in the red for 2022. At the other end of the spectrum is an unlikely collection of stocks that have boldly bucked the market trend.
The Zacks Analyst Blog Highlights UnitedHealth, Chevron, AstraZeneca, SAP and Bayer ktiengesellschaftt
03:04pm, Monday, 27'th Jun 2022 Zacks Investment Research
UnitedHealth, Chevron, AstraZeneca, SAP and Bayer ktiengesellschaftt are part of Zacks top Analyst Blog.
AstraZeneca-Daiichi Sankyo Enhertu breast cancer drug recommended for EU approval
11:34am, Monday, 27'th Jun 2022 MarketWatch
The decision was based on trial results showing that Enhertu cut the risk of disease progression or death by 72% compared with the trastuzumab emtansine drug.
2 Stocks That Could Survive the Next Recession
11:30am, Monday, 27'th Jun 2022 The Motley Fool
They have done it before.
AstraZeneca Enhertu breast cancer drug is recommended for EU approval
03:11am, Monday, 27'th Jun 2022
AstraZeneca PLC said Monday that its Enhertu drug has been recommended for approval in the European Union for patients with breast cancer.
Top Analyst Reports for UnitedHealth, Chevron & AstraZeneca
07:01pm, Friday, 24'th Jun 2022 Zacks Investment Research
Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group Incorporated (UNH), Chevron Corporation (CVX), and AstraZeneca PLC (AZN).
Astrazeneca (AZN) Gains As Market Dips: What You Should Know
10:15pm, Wednesday, 22'nd Jun 2022 Zacks Investment Research
In the latest trading session, Astrazeneca (AZN) closed at $63.55, marking a +1.15% move from the previous day.
2 Safe Stocks to Buy in This Bear Market
03:00pm, Wednesday, 22'nd Jun 2022 The Motley Fool
They both pay dividends and have some great growth potential.
2 Safe Stocks to Buy in This Bear Market
11:00am, Wednesday, 22'nd Jun 2022
They both pay dividends and have some great growth potential.
Ionis (IONS), AstraZeneca's Amyloidosis Drug Meets Study Goals
01:32pm, Tuesday, 21'st Jun 2022 Zacks Investment Research
Ionis (IONS), along with partner AstraZeneca, reports positive data from a phase III study, which is evaluating eplontersen in hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).
AstraZeneca, Ionis plan to seek FDA approval for rare-disease therapy this year
11:19am, Tuesday, 21'st Jun 2022
U.S.-listed shares of AstraZeneca AZN, +2.98% were up 2.5% in trading on Tuesday after the company said an experimental therapy for hereditary transthyretin-mediated amyloid polyneuropathy met its pri
4 of the Safest Stocks to Buy If the U.S. Dips Into a Recession
09:06am, Tuesday, 21'st Jun 2022 The Motley Fool
These rock-solid companies can help investors navigate a market rife with recession risk.
4 of the Safest Stocks to Buy If the U.S. Dips Into a Recession
05:06am, Tuesday, 21'st Jun 2022
These rock-solid companies can help investors navigate a market rife with recession risk.
AstraZeneca hails phase III success of drug for rare disease amyloid polyneuropathy
03:34am, Tuesday, 21'st Jun 2022
AstraZeneca PLC (LSE:AZN) will file a new drug application later this year after a successful phase III clinical trial of a treatment for a rare hereditary disease. Eplontersen hit all its goals when
